[
    [
        {
            "time": "2021-03-17",
            "original_text": "Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline",
            "features": {
                "keywords": [
                    "donanemab",
                    "amyloid plaque",
                    "cognitive decline"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-14",
            "original_text": "U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir",
            "features": {
                "keywords": [
                    "FDA",
                    "COVID-19",
                    "remdesivir"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-19",
            "original_text": "FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen",
            "features": {
                "keywords": [
                    "FDA",
                    "baricitinib",
                    "emergency use",
                    "COVID-19"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-12",
            "original_text": "Lilly, Kumquat Biosciences Team Up To Discover, Develop Immuno-Oncology Candidates",
            "features": {
                "keywords": [
                    "Lilly",
                    "Kumquat Biosciences",
                    "Immuno-Oncology"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly, Kumquat Biosciences Team Up To Discover, Develop Immuno-Oncology Candidates",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-12",
            "original_text": "Lilly signs deal with Kumquat Biosciences",
            "features": {
                "keywords": [
                    "Lilly",
                    "Kumquat Biosciences",
                    "deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly signs deal with Kumquat Biosciences",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-12",
            "original_text": "Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses",
            "features": {
                "keywords": [
                    "Lilly",
                    "Kumquat Biosciences",
                    "Collaboration",
                    "Small Molecules",
                    "Immune Responses"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]